Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Komal Jhaveri ,Antonio Breast Cancer Symposium ,Anastrozole ,Fulvestrant ,Trastuzumab Deruxtecan ,Nct04556773 ,Destiny Breast08 ,